MODD · Modular Medical, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“Even with these proceeds, we do not believe that our cash and cash equivalents will be sufficient to fund our operations for the period of 12 months from the date of issuance of this report, and we would need to raise additional capital. As a result of our expected operating losses and cash burn for the foreseeable future and recurring losses from operations, if we are unable to raise sufficient capital through additional debt or equity arrangements, there will be uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt as to our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| $61 | — | — | — | — | $368.92K | $130 | $28.75K | $39.39K | $8518 | $962 | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| $19.21M | $19.97M | $14.7M | $12.88M | $9.06M | $7.73M | $4.08M | $3.03M | $1.88M | $332.64K | $0 | — | — | — | — | — | |
| $8.08M | $7.59M | $4.35M | $4.65M | $4.82M | $7.2M | $3.25M | $2.31M | $694.95K | $98.7K | $91.05K | $13.16K | $16.12K | $10.77K | $10.92K | $9513 | |
| $1.76M | $1.67M | $1.06M | $426K | $152K | $117.49K | $111.02K | $35.43K | $14.47K | $1861 | $0 | — | — | $0 | $0 | $0 | |
| $27.29M | $27.56M | $19.05M | $17.53M | $13.88M | $14.93M | $7.34M | $5.35M | $2.58M | $666.16K | $29.42K | — | — | — | — | — | |
| -$27.29M | -$27.56M | -$19.05M | -$17.53M | -$13.88M | -$14.93M | -$7.34M | -$5.35M | -$2.58M | -$666.16K | -$91.05K | -$13.16K | -$16.12K | -$10.77K | -$10.92K | -$9513 | |
| -$25.53M | -$25.89M | -$17.99M | -$17.1M | -$13.73M | -$14.81M | -$7.23M | -$5.31M | -$2.56M | -$664.3K | — | — | — | -$10.77K | -$10.92K | -$9513 | |
| — | — | — | — | — | $2.75M | $39.79K | $0 | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | -$17.92K | -$14.88K | — | -$9870 | -$7979 | |
| — | -$28.24M | -$18.82M | -$17.47M | -$13.88M | -$18.63M | -$7.38M | -$5.32M | -$2.54M | -$657.65K | -$106.56K | -$31.08K | -$30.99K | — | — | — | |
| — | $2000 | $2000 | $2000 | $2000 | $1600 | $1600 | $1600 | $1589 | $1600 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$28.03M | -$28.24M | -$18.82M | -$17.47M | -$13.88M | -$18.63M | -$7.38M | -$5.32M | -$2.54M | -$659.25K | -$106.56K | -$31.08K | -$30.99K | -$22.79K | -$20.79K | -$17.49K | |
| USD/shares | -$9.85 | -$12.36 | -$15.26 | -$23.40 | -$34.50 | -$82.20 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$9.85 | -$12.36 | -$15.26 | -$23.40 | -$34.50 | -$82.20 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 2.29M | 1.23M | 745.9K | 403.43K | 226.92K | 621.16K | 595.49K | 552.99K | 444.54K | 55.05K | 41.66K | 41.66K | 41.66K | 41.66K | 41.66K |
| shares | — | 2.29M | 1.23M | 745.9K | 403.43K | 226.92K | 621.16K | 595.49K | 552.99K | 444.54K | 55.05K | 41.66K | 41.66K | 41.66K | 41.66K | 41.66K |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2018: $14.1K in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2026-06-30 | USD 278,000 | 10-Q filed 2026-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 70 similar-size Medical Devices companies (of 156 listed).